Adverse events during CT colonography for screening, diagnosis and preoperative staging of colorectal cancer: a Japanese national survey

Nagata, Kôichi; Takabayashi, Ken; Yasuda, Tamotsu; Hirayama, Michiaki; Endo, Shunsuke; Nozaki, Ryoichi; Shimada, Toshio; Kanazawa, Hideko; Fujiwara, Masanori; Shimizu, Norihito; Iwatsuki, Tatema; Iwano, Teruaki; Saitō, Hiroshi

doi:10.1007/s00330-017-4920-y

Cited by 21 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2015, a Japanese national survey of 147 439 CTC examinations [58] revealed lower perforation rates of 0.014 % overall, albeit with a higher rate when CTC was used for preoperative staging (0.028 %); and a much lower rate for screening RECOMMENDATION ESGE/ESGAR suggest CTC in patients with high risk polyps undergoing surveillance after polypectomy only when colonoscopy is unfeasible. Weak recommendation, low quality evidence.…”

Section: Other Indications and Contraindications For Ctc: Diverticulamentioning

confidence: 99%

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020

et al. 2020

View full text Add to dashboard Cite

Main recommendations 1 ESGE/ESGAR recommend computed tomographic colonography (CTC) as the radiological examination of choice for the diagnosis of colorectal neoplasia.Strong recommendation, high quality evidence.ESGE/ESGAR do not recommend barium enema in this setting.Strong recommendation, high quality evidence. 2 ESGE/ESGAR recommend CTC, preferably the same or next day, if colonoscopy is incomplete. The timing depends on an interdisciplinary decision including endoscopic and radiological factors.Strong recommendation, low quality evidence.ESGE/ESGAR suggests that, in centers with expertise in and availability of colon capsule endoscopy (CCE), CCE preferably the same or the next day may be considered if colonoscopy is incomplete.Weak recommendation, low quality evidence. 3 When colonoscopy is contraindicated or not possible, ESGE/ESGAR recommend CTC as an acceptable and equally sensitive alternative for patients with alarm symptoms.Strong recommendation, high quality evidence.Because of lack of direct evidence, ESGE/ESGAR do not recommend CCE in this situation.Very low quality evidence.ESGE/ESGAR recommend CTC as an acceptable alternative to colonoscopy for patients with non-alarm symptoms.Strong recommendation, high quality evidence.In centers with availability, ESGE/ESGAR suggests that CCE may be considered in patients with non-alarm symptoms.Weak recommendation, low quality evidence. 4 Where there is no organized fecal immunochemical test (FIT)-based population colorectal screening program, ESGE/ESGAR recommend CTC as an option for colorectal cancer screening, providing the screenee is adequately informed about test characteristics, benefits, and risks, and depending on local service- and patient-related factors.Strong recommendation, high quality evidence.ESGE/ESGAR do not suggest CCE as a first-line screening test for colorectal cancer.Weak recommendation, low quality evidence. 5 ESGE/ESGAR recommend CTC in the case of a positive fecal occult blood test (FOBT) or FIT with incomplete or unfeasible colonoscopy, within organized population screening programs.Strong recommendation, moderate quality evidence.ESGE/ESGAR also suggest the use of CCE in this setting based on availability.Weak recommendation, moderate quality evidence. 6 ESGE/ESGAR suggest CTC with intravenous contrast medium injection for surveillance after curative-intent resection of colorectal cancer only in patients in whom colonoscopy is contraindicated or unfeasibleWeak recommendation, low quality evidence.There is insufficient evidence to recommend CCE in this setting.Very low quality evidence. 7 ESGE/ESGAR suggest CTC in patients with high risk polyps undergoing surveillance after polypectomy only when colonoscopy is unfeasible.Weak recommendation, low quality evidence.There is insufficient evidence to recommend CCE in post-polypectomy surveillance.Very low quality evidence. 8 ESGE/ESGAR recommend against CTC in patients with acute colonic inflammation and in those who have recently undergone colorectal surgery, pending a multidisciplinary evaluation.Strong recommendation, low quality evidence. 9 ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least one polyp ≥ 6 mm detected at CTC or CCE.Follow-up CTC may be clinically considered for 6 – 9-mm CTC-detected lesions if patients do not undergo polypectomy because of patient choice, comorbidity, and/or low risk profile for advanced neoplasia.Strong recommendation, moderate quality evidence.

show abstract

Section: Other Indications and Contraindications For Ctc: Diverticulamentioning

confidence: 99%

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Die CTK ist eine minimal-invasive und für Patienten sichere Untersuchungsmethode. So wurden bislang keine CTK-assoziierten Todesfälle dokumentiert [16,47]. Die CTK-assoziierten Perforationsraten bei asymptomatischen Vorsorgepatienten sind sehr gering und liegen gemäß einer aktuellen Studie bei 0,003 % [47].…”

Section: Komplikationenunclassified

“…So wurden bislang keine CTK-assoziierten Todesfälle dokumentiert [16,47]. Die CTK-assoziierten Perforationsraten bei asymptomatischen Vorsorgepatienten sind sehr gering und liegen gemäß einer aktuellen Studie bei 0,003 % [47]. Damit sind sie in etwa 10-mal geringer als bei der Vorsorgekoloskopie [15].…”

Section: Komplikationenunclassified

See 1 more Smart Citation

Kolorektales Karzinom: Rolle bildgebender Verfahren in der Vorsorge

Mang

2018

Radiologe

View full text Add to dashboard Cite

Das kolorektale Karzinom (CRK) ist mit einer Inzidenz von 30 Neuerkrankungen pro 100.000 Einwohner pro Jahr in Europa bei Frauen das zweit-und bei Männern das dritthäufigste Karzinom. Es hat unter den Krebserkrankungen nach dem Bronchialkarzinom die zweithöchste Mortalität. In Europa erkrankten im Jahr 2018 Jahr knapp 500.000 Menschen am kolorektalen Karzinom; über 240.000 sterben daran [1]. Das Lebenszeitrisiko, an einem kolorektalen Karzinom zu erkranken, beträgt rund 6 %. Ab dem 50. Lebensjahr nimmt die Rate der Neuerkrankungen deutlich zu. Der Altersgipfel liegt um das 65. bis 75. Lebensjahr. Die Inzidenz des kolorektalen Karzinoms ist bei Männern höher als bei Frauen. Die überwiegende Mehrheit der kolorektalen Karzinome entwickeln sich über einen langen Zeitraum aus einer gutartigen Vorläuferläsion (. Abb. 1). Dieser Entwicklungsprozess erfolgt entlang zweier verschiedener Karzinogenesewege, der klassischen Adenom-Karzinom-Sequenz und dem sog. serratierten Karzinogeneseweg.

show abstract

“…During screening or diagnosing colonoscopies, the overall adverse event rate has been reported to be around 2.8 per 1000 acts [6]. Even with computed tomographic (CT) colonography, a recent study including 431 Japanese centres with 147,439 CT examinations showed 0.014% of colorectal perforations [7]. In addition, tissue biopsies are also time-consuming.…”

Section: Introductionmentioning

confidence: 99%

Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

Christou

Meyer

Popeskou

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Despite many advances in the diagnosis and treatment of colorectal cancer (CRC), its incidence and mortality rates continue to make an impact worldwide and in some countries rates are mounting. Over the past decade, liquid biopsies have been the object of fundamental and clinical research with regard to the different steps of CRC patient care such as screening, diagnosis, prognosis, follow-up, and therapeutic response. They are attractive because they are considered to encompass both the cellular and molecular heterogeneity of tumours. They are easily accessible and can be applied to large-scale settings despite the cost. However, liquid biopsies face drawbacks in detection regardless of whether we are testing for circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), or miRNA. This review highlights the different advantages and disadvantages of each type of blood-based biopsy and underlines which specific one may be the most useful and informative for each step of CRC patient care.

show abstract

Adverse events during CT colonography for screening, diagnosis and preoperative staging of colorectal cancer: a Japanese national survey

Cited by 21 publications

References 23 publications

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020

Kolorektales Karzinom: Rolle bildgebender Verfahren in der Vorsorge

Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

Contact Info

Product

Resources

About